Subcutaneous C5 Inhibitor Approved for PNH

[MEDPAGE TODAY]( Oncology Update Tuesday, June 25, 2024 [Subcutaneous C5 Inhibitor Approved for PNH]( [ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer]( [Acupuncture Reduced Hot Flashes Related to Endocrine Therapy for Breast Cancer]( [Adagrasib Wins Accelerated Approval for KRAS-Mutant Colorectal Cancer]( [Court: Some Employers Can Exclude PrEP, Cancer Screenings From Insurance Coverage]( ADVERTISEMENT Exclusives & Features [Docs in Abortion Ban States Find Workarounds to Deliver Care]( Industry Clinic Ad Insights [What Will It Take to Deliver Both Health & Care in Oncology?]( [Tumour-intrinsic features shape T-cell differentiation through myeloma disease evolution]( The haematological malignancy multiple myeloma is associated with skewed T-cell activation and function. T-cell alterations are detectable in asymptomatic myeloma precursor conditions and have the... [READ MORE]( [A Third Of Younger Women In England Aren’t Getting Key Cancer Test]( Cervical screenings can be uncomfortable, embarrassing and even painful. But the lifesaving tests are a key tool in the fight against cervical cancer. [READ MORE]( [Air Pollution Makes Cancer Patients More Vulnerable To Cardiovascular Disease]( Even short-term exposure to air pollutants known as fine particulate matter 2.5 (PM2.5) s linked to a significantly greater risk of cancer patients suffering from and/or dying due to cardiovascular... [READ MORE]( [IDH1 mutation is associated with improved resection rates, progression-free survival and overall survival in patients with anaplastic astrocytomas.]( PURPOSE: The introduction of molecular markers in to the diagnosis of gliomas has changed the therapeutic approach to this tumors. The aim of this study was to examine the impact of surgery on... [READ MORE]( [Detecting small cell transformation in patients with advanced EGFR mutant lung adenocarcinoma through epigenomic cfDNA profiling.]( PURPOSE: Histologic transformation to small cell lung cancer (SCLC) is a mechanism of treatment resistance in patients with advanced oncogene-driven lung adenocarcinoma (LUAD) that currently requires... [READ MORE]( [A Property of Everyday Health group]( © 2024 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_Spec_Oncology_Update?xid=nl_mpt_Oncology_update_2024-06-25&mh=3c4cdd242849aa0e970f25e401732f81) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 5th Avenue, 15th Floor New York, NY 10011